Fig. 1From: One of the 5-aminosalicylates drug, mesalamine as a drug repurposing lead against breast cancerDocked images of EGFR, ERα, and Aromatase with mesalamine, showing various interactions within the complex. 3D image of binding of the ligand with A EGFR, B ERα, and C Aromatase. 2D diagram involving various amino acid residues after docking of the ligand with a EGFR, b ERα, and c AromataseBack to article page